|
EP1487417A4
(en)
|
2001-09-17 |
2010-03-17 |
Glaxo Group Ltd |
DRY POWDER DRUG FORMULATIONS
|
|
DE60320007T2
(de)
|
2002-10-28 |
2009-06-18 |
Glaxo Group Ltd., Greenford |
Phenthanolamin-Derivate zur Behandlung von Atemwegserkrankungen
|
|
GB0316290D0
(en)
|
2003-07-11 |
2003-08-13 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
|
GB0418045D0
(en)
|
2004-08-12 |
2004-09-15 |
Glaxo Group Ltd |
Compounds
|
|
GT200500281A
(es)
|
2004-10-22 |
2006-04-24 |
Novartis Ag |
Compuestos organicos.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
JP5281291B2
(ja)
|
2005-01-10 |
2013-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
GB0516313D0
(en)
|
2005-08-08 |
2005-09-14 |
Argenta Discovery Ltd |
Azole derivatives and their uses
|
|
RU2442771C2
(ru)
|
2005-08-08 |
2012-02-20 |
Арджента Дискавери Лтд |
Производные бицикло[2,2,1]гепт-7-иламина и их применения
|
|
EP2532677A1
(en)
|
2005-10-21 |
2012-12-12 |
Novartis AG |
Human antibodies against il13 and therapeutic uses
|
|
PE20071068A1
(es)
|
2005-12-20 |
2007-12-13 |
Glaxo Group Ltd |
Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
EA200801997A1
(ru)
|
2006-04-20 |
2009-04-28 |
Глаксо Груп Лимитед |
Новые соединения
|
|
HRP20120494T1
(hr)
|
2006-04-21 |
2012-08-31 |
Novartis Ag |
Derivati purina za uporabu kao agonista adenozin a2a receptora
|
|
GB0611587D0
(en)
|
2006-06-12 |
2006-07-19 |
Glaxo Group Ltd |
Novel compounds
|
|
CL2007001829A1
(es)
|
2006-06-23 |
2008-01-25 |
Smithkline Beecham Corp |
P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
|
|
NZ574533A
(en)
|
2006-08-01 |
2011-05-27 |
Glaxo Group Ltd |
Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
|
|
AU2007342223B2
(en)
|
2007-01-10 |
2011-02-24 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
|
CA2676173A1
(en)
*
|
2007-02-16 |
2008-08-28 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
|
|
AR065804A1
(es)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
|
|
EP2332933A1
(en)
|
2007-05-07 |
2011-06-15 |
Novartis AG |
Epithelial sodium channel (ENaC) inhibitors
|
|
BRPI0820669A2
(pt)
|
2007-12-10 |
2020-08-04 |
Novartis Ag |
compostos orgânicos
|
|
JP5584138B2
(ja)
|
2008-01-11 |
2014-09-03 |
ノバルティス アーゲー |
キナーゼ阻害剤としてのピリミジン類
|
|
JP5791500B2
(ja)
|
2008-05-23 |
2015-10-07 |
パンミラ ファーマシューティカルズ，エルエルシー． |
５−リポキシゲナーゼ活性化タンパク質阻害剤
|
|
EP2280946B1
(en)
|
2008-06-05 |
2016-02-10 |
Glaxo Group Limited |
4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
|
|
KR20110040818A
(ko)
|
2008-06-10 |
2011-04-20 |
노파르티스 아게 |
상피 나트륨 채널 차단제로서의 피라진 유도체
|
|
US8236786B2
(en)
|
2008-08-07 |
2012-08-07 |
Pulmagen Therapeutics (Inflammation) Limited |
Respiratory disease treatment
|
|
PL2379507T3
(pl)
|
2008-12-30 |
2014-03-31 |
Pulmagen Therapeutics Inflammation Ltd |
Związki sulfonamidu do leczenia zaburzeń układu oddechowego
|
|
WO2010094643A1
(en)
|
2009-02-17 |
2010-08-26 |
Glaxo Group Limited |
Quinoline derivatives and their uses for rhinitis and urticaria
|
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
|
US8354539B2
(en)
|
2009-03-10 |
2013-01-15 |
Glaxo Group Limited |
Indole derivatives as IKK2 inhibitors
|
|
JP2012520845A
(ja)
|
2009-03-17 |
2012-09-10 |
グラクソ グループ リミテッド |
Ｉｔｋ阻害剤として使用されるピリミジン誘導体
|
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
|
AU2010226604A1
(en)
|
2009-03-19 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of BTB and CNC homology 1, basic leucine zipper transcription factor 1 (Bach 1) gene expression using short interfering nucleic acid (siNA) sequence listing
|
|
JP2012520683A
(ja)
|
2009-03-19 |
2012-09-10 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
|
|
US20120035247A1
(en)
|
2009-03-19 |
2012-02-09 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 6 (STAT6) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
WO2010111468A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
|
WO2010111490A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
|
EP2411517A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
WO2010122088A1
(en)
|
2009-04-24 |
2010-10-28 |
Glaxo Group Limited |
Pyrazole and triazole carboxamides as crac channel inhibitors
|
|
US8399436B2
(en)
|
2009-04-24 |
2013-03-19 |
Glaxo Group Limited |
N-pyrazolyl carboxamides as CRAC channel inhibitors
|
|
RS53830B1
(sr)
|
2009-04-30 |
2015-06-30 |
Glaxo Group Limited |
Indazoli supstituisani oksazolom kao inhibitori pi3-kinaze
|
|
WO2010150014A1
(en)
|
2009-06-24 |
2010-12-29 |
Pulmagen Therapeutics (Inflammation) Limited |
5r- 5 -deuterated glitazones for respiratory disease treatment
|
|
AU2010310449A1
(en)
|
2009-10-22 |
2012-05-03 |
Vertex Pharmaceuticals Incorporated |
Compositions for treatment of cystic fibrosis and other chronic diseases
|
|
GB0918923D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminothiazole derivatives
|
|
GB0918922D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Aminopyridine derivatives
|
|
GB0918924D0
(en)
|
2009-10-28 |
2009-12-16 |
Vantia Ltd |
Azaindole derivatives
|
|
WO2011067365A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Benzpyrazole derivatives as inhibitors of p13 kinases
|
|
EP2507231A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Indazole derivatives as pi 3 - kinase inhibitors
|
|
WO2011067364A1
(en)
|
2009-12-03 |
2011-06-09 |
Glaxo Group Limited |
Novel compounds
|
|
US20120272951A1
(en)
|
2009-12-16 |
2012-11-01 |
3M Innovative Properties Company |
Formulations and methods for controlling mdi particle size delivery
|
|
WO2011098746A1
(en)
|
2010-02-09 |
2011-08-18 |
Pulmagen Therapeutics (Inflammation) Limited |
Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
|
|
GB201002243D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
GB201002224D0
(en)
|
2010-02-10 |
2010-03-31 |
Argenta Therapeutics Ltd |
Respiratory disease treatment
|
|
WO2011110575A1
(en)
|
2010-03-11 |
2011-09-15 |
Glaxo Group Limited |
Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
GB201007203D0
(en)
|
2010-04-29 |
2010-06-16 |
Glaxo Group Ltd |
Novel compounds
|
|
HRP20151017T1
(hr)
|
2010-09-08 |
2015-10-23 |
Glaxosmithkline Intellectual Property Development Limited |
Polimorfi i soli n-[5-[4-(5-{[(2r,6s)-2,6-dimetil-4-morfolinil]metil}-1,3-oksazol-2-il)-1h-indazol-6-il]-2-(metiloksi)-3-piridinil]metansulfonamida
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
UY33597A
(es)
|
2010-09-09 |
2012-04-30 |
Irm Llc |
Compuestos y composiciones como inhibidores de la trk
|
|
WO2012035055A1
(en)
|
2010-09-17 |
2012-03-22 |
Glaxo Group Limited |
Novel compounds
|
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
|
JP5795643B2
(ja)
|
2010-10-21 |
2015-10-14 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
アレルギー性状態、免疫性状態及び炎症性状態に作用するピラゾール化合物
|
|
WO2012052459A1
(en)
|
2010-10-21 |
2012-04-26 |
Glaxo Group Limited |
Pyrazole compounds acting against allergic, inflammatory and immune disorders
|
|
GB201018124D0
(en)
|
2010-10-27 |
2010-12-08 |
Glaxo Group Ltd |
Polymorphs and salts
|
|
BR112013021638A2
(pt)
|
2011-02-25 |
2016-08-02 |
Irm Llc |
"compostos inibidores de trk, seu uso e composições que os compreendem"
|
|
GB201104153D0
(en)
|
2011-03-11 |
2011-04-27 |
Glaxo Group Ltd |
Novel compounds
|
|
US20140005188A1
(en)
|
2011-03-11 |
2014-01-02 |
Glaxo Group Limited |
Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
|
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
|
WO2013038378A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
WO2013038381A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine/pyrazine amide derivatives
|
|
JP6165733B2
(ja)
|
2011-09-16 |
2017-07-19 |
ノバルティス アーゲー |
Ｎ−置換ヘテロシクリルカルボキサミド類
|
|
WO2013038373A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
Pyridine amide derivatives
|
|
CN103946221B
(zh)
|
2011-09-16 |
2016-08-03 |
诺华股份有限公司 |
用于治疗囊性纤维化的杂环化合物
|
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
|
KR20160062179A
(ko)
|
2013-10-17 |
2016-06-01 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
호흡기 질병의 치료를 위한 ｐｉ３ｋ 억제제
|
|
EP3057588A1
(en)
|
2013-10-17 |
2016-08-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Pi3k inhibitor for treatment of respiratory disease
|
|
AU2014391610B2
(en)
|
2014-04-24 |
2018-01-25 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
KR20160145780A
(ko)
|
2014-04-24 |
2016-12-20 |
노파르티스 아게 |
포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
|
|
CA2945212A1
(en)
|
2014-04-24 |
2015-10-29 |
Novartis Ag |
Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
|
WO2015173701A2
(en)
|
2014-05-12 |
2015-11-19 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Pharmaceutical compositions for treating infectious diseases
|
|
US12084472B2
(en)
|
2015-12-18 |
2024-09-10 |
Ardelyx, Inc. |
Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
|
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
|
|
GB201602527D0
(en)
|
2016-02-12 |
2016-03-30 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
EP3497100A1
(en)
|
2016-08-08 |
2019-06-19 |
GlaxoSmithKline Intellectual Property Development Limited |
Chemical compounds
|
|
GB201706102D0
(en)
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
GB201712081D0
(en)
|
2017-07-27 |
2017-09-13 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
|
US20200383960A1
(en)
|
2019-06-10 |
2020-12-10 |
Novartis Ag |
Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
|
|
KR20220052934A
(ko)
|
2019-08-28 |
2022-04-28 |
노파르티스 아게 |
치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도
|
|
WO2023097697A1
(zh)
*
|
2021-12-03 |
2023-06-08 |
广东莱佛士制药技术有限公司 |
一种合成(1r)-1-(2,2-二甲基-4h-1,3-苯并二噁英-6-基)噁唑啉-2-酮的方法
|